Company / R&D Expense
Sunshine Biopharma Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$933.9K
FY2025
5-year range
$1.7K / $1.9M
FY2021-FY2025
Trend
-49.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 10 years, ranging from $0 in FY2018 to $2M in FY2024.
Based on SEC 10-K filings.
$933,902 in FY2025 with a 5-year CAGR of +127.9%.
Improved from $811,858 to $933,902 over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +11.6%
- 5-Year CAGR
- +127.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +127.9%, indicating consistent growth.
- In FY2025, r&d expense decreased 49.7% year-over-year.
- Peak r&d expense was recorded in FY2024.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $933.9K | -49.7% |
| FY2024 | $1.9M | +128.6% |
| FY2023 | $811.9K | +20.8% |
| FY2022 | $672.2K | +38801.0% |
| FY2021 | $1.7K | -88.6% |
| FY2020 | $15.2K | +18.8% |
| FY2019 | $12.8K | - |
| FY2018 | $0 | -100.0% |
| FY2017 | $32.8K | +278.8% |
| FY2016 | $8.7K | -97.4% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026